Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
劳拉替尼联合或不联合化疗治疗ALK驱动的难治性/复发性神经母细胞瘤:1期临床试验结果
期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-023-02297-5
Goldsmith, Kelly C; Park, Julie R; Kayser, Kimberly; Malvar, Jemily; Chi, Yueh-Yun; Groshen, Susan G; Villablanca, Judith G; Krytska, Kateryna; Lai, Lillian M; Acharya, Patricia T; Goodarzian, Fariba; Pawel, Bruce; Shimada, Hiroyuki; Ghazarian, Susan; States, Lisa; Marshall, Lynley; Chesler, Louis; Granger, Meaghan; Desai, Ami V; Mody, Rajen; Morgenstern, Daniel A; Shusterman, Suzanne; Macy, Margaret E; Pinto, Navin; Schleiermacher, Gudrun; Vo, Kieuhoa; Thurm, Holger C; Chen, Joseph; Liyanage, Marlon; Peltz, Gerson; Matthay, Katherine K; Berko, Esther R; Maris, John M; Marachelian, Araz; Mossé, Yael P